San Francisco, CA – October 26, 2023 – BigHat Biosciences, a pioneering biotechnology company leveraging artificial intelligence to accelerate antibody discovery and development, has announced a significant milestone with the dosing of the first patient in a Phase I clinical trial for BHB810. This novel antibody-drug conjugate (ADC) is being investigated for the treatment of advanced gastric cancer and other gastrointestinal (GI) malignancies, marking a critical step in validating BigHat’s AI platform’s ability to translate AI-generated designs into clinic-ready therapeutics.
n
The trial will focus on patients with advanced gastric and gastroesophageal tumors, specifically administering BHB810, an ADC designed to target Cadherin-17 (CDH17). CDH17 is a protein that is frequently overexpressed in various GI cancers, making it a promising target for therapeutic intervention. This development signifies a potential new avenue for patients facing these aggressive and often difficult-to-treat cancers.
n
Main Facts: A New Hope for GI Cancer Patients
n
BigHat Biosciences has officially initiated its Phase I clinical trial for BHB810, a cutting-edge antibody-drug conjugate. The primary goal of this trial is to rigorously assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumour activity of BHB810 in patients battling advanced gastric and gastroesophageal tumours. The investigational therapy is specifically designed to target Cadherin-17 (CDH17), a protein known to be highly expressed in these types of cancers, presenting a significant therapeutic opportunity.
n
The trial will initially enroll patients whose tumours exhibit demonstrable CDH17 expression. This targeted approach ensures that the drug is administered to those most likely to benefit, maximizing the potential for positive outcomes and providing valuable data on the drug’s efficacy in its intended patient population.
n
BHB810 itself represents a sophisticated therapeutic approach, engineered as a VHH-Fc antibody-drug conjugate. Its development was significantly accelerated by BigHat Biosciences’ proprietary AI platform, which is designed to identify and optimize antibody candidates with unprecedented speed and precision. The compact structure of the VHH antibody, coupled with advanced payload technology, is expected to contribute to both therapeutic efficacy and an improved safety profile, as suggested by promising preclinical studies.
n
Chronology: From AI Design to Human Trials
n
The journey of BHB810 from concept to clinical trial is a testament to the power of AI in modern drug development. BigHat Biosciences’ AI platform played a pivotal role in identifying the CDH17 target and subsequently designing the optimal antibody construct for BHB810. This AI-driven discovery process allowed for rapid iteration and optimization, significantly shortening the traditional drug development timeline.
n
Preclinical Validation: Before reaching human trials, BHB810 underwent extensive preclinical testing. These studies encompassed nearly 30 patient-derived and cell-derived tumor models. Crucially, these models included those with both low and heterogeneous CDH17 expression, providing a comprehensive understanding of BHB810’s potential efficacy across a range of tumor microenvironments. The results from these preclinical investigations were highly encouraging, with BHB810 demonstrating complete or near-complete tumor clearance in a substantial number of these models. This robust preclinical data provided the foundation for the progression into human clinical trials.
n
AI-Generated Design to Clinic-Ready Therapeutic: The successful transition of BHB810 from an AI-generated design into a clinical-stage therapeutic is a landmark achievement for BigHat Biosciences. It validates the company’s core hypothesis: that AI can effectively identify and develop novel antibody candidates that are not only potent but also possess the necessary characteristics for successful clinical translation. This achievement underscores the transformative potential of AI in the pharmaceutical industry, promising to accelerate the delivery of much-needed therapies to patients.
n
Broader Pipeline Advancement: The development of BHB810 is part of a broader strategic vision for BigHat Biosciences. The company is actively progressing other investigational therapies, including BHB299, a T-cell engager targeting CEACAM6 for solid tumors, which is slated for clinical studies in 2027. This indicates a sustained commitment to building a diverse pipeline of innovative treatments across various oncology indications.
n
Strategic Collaborations: BigHat Biosciences has also forged strategic collaborations with leading pharmaceutical companies. These partnerships, including those with Johnson & Johnson and Merck (MSD), highlight the industry’s recognition of BigHat’s AI capabilities and its potential to generate valuable antibody therapeutics. A significant recent development was the April 2025 research deal with Eli Lilly, aimed at co-developing next-generation antibody therapeutics, further solidifying BigHat’s position at the forefront of AI-driven drug discovery.
n
Supporting Data: Preclinical Efficacy and Safety Profile
n
The preclinical data supporting BHB810’s advancement into clinical trials is particularly compelling. The VHH-Fc antibody-drug conjugate demonstrated remarkable efficacy in a wide array of tumor models.
n
Tumor Clearance: In preclinical studies, BHB810 consistently induced complete or near-complete tumor clearance across nearly 30 diverse patient-derived and cell-derived tumor models. This level of efficacy, particularly in models with challenging CDH17 expression patterns, suggests a potent anti-cancer mechanism of action. The ability of BHB810 to overcome challenges associated with heterogeneous target expression is a critical differentiator, potentially expanding its applicability to a broader patient population.
n
Safety and Tolerability: Beyond efficacy, the preclinical investigations also focused on the safety profile of BHB810. The unique characteristics of the VHH antibody structure, known for its compact size and high affinity, combined with BigHat’s stable payload technology, contributed to a promising safety profile in animal studies. This suggests a favorable therapeutic window, a crucial factor for the success of any new cancer therapy, especially for patients who may already be undergoing or have undergone prior treatments. The reduced off-target binding potential often associated with smaller antibody formats like VHHs could translate to fewer dose-limiting toxicities in human trials, allowing for potentially higher and more effective doses.
n
The meticulous preclinical work has laid a strong foundation for the ongoing Phase I trial, providing confidence in BHB810’s potential to offer a safe and effective treatment option for patients with advanced GI cancers.
n
Official Responses: A Vision for AI-Driven Therapeutics
n
The commencement of the BHB810 clinical trial has been met with considerable enthusiasm from BigHat Biosciences’ leadership, underscoring the company’s strategic vision and its belief in the transformative power of its AI platform.
n
Peyton Greenside, Co-founder and CEO of BigHat Biosciences, articulated the significance of this milestone: "The treatment of the first patient with BHB810 marks an important step forward in our mission to enable transformative AI-designed therapeutics and comes during a period of steady momentum for BigHat, as we continue to advance both our pipeline of novel therapeutics and AI platform."
n
Greenside further emphasized the validation of their AI approach: "This is the first program we’ve taken from AI-generated design into human studies, validating the ability of our platform to identify and develop promising antibodies into clinic-ready therapeutics." This statement highlights the company’s commitment to not just discovery but also the rigorous development and translation of AI-generated candidates.
n
The potential impact of BHB810 on patient care was also a central theme in the CEO’s remarks: "BHB810 could offer a differentiated approach to address a target that has been difficult to drug well, and we are excited by the potential to offer a much-needed new treatment option for patients living with GI cancers." This underscores the unmet medical need in the GI cancer landscape and BigHat’s ambition to fill that void with innovative, AI-driven solutions. The targeting of CDH17, a notoriously challenging target, further emphasizes the sophistication and potential of their AI platform to overcome such hurdles.
n
The broader context of BigHat’s ongoing development and strategic partnerships, including the significant deal with Eli Lilly, signals a company on a strong upward trajectory. These collaborations not only provide financial and developmental support but also serve as external validation of BigHat’s technological prowess and its ability to generate high-value therapeutic candidates. The continuous advancement of their pipeline, exemplified by BHB299 and the ongoing success with BHB810, paints a clear picture of a company dedicated to pushing the boundaries of what is possible in therapeutic development.
n
Implications: Reshaping the Future of Oncology Drug Development
n
The successful initiation of the BHB810 clinical trial carries significant implications for the future of oncology drug development, particularly in the realm of AI-driven therapeutics.
n
Accelerated Drug Discovery and Development: BigHat Biosciences’ achievement demonstrates that AI is not merely a theoretical concept but a practical tool capable of dramatically accelerating the drug discovery and development pipeline. The ability to move from AI-generated design to human trials rapidly signifies a paradigm shift, potentially bringing life-saving treatments to patients much faster than traditional methods. This could lead to a more efficient allocation of resources within the pharmaceutical industry and a quicker response to emerging health crises.
n
Unlocking Difficult-to-Drug Targets: The development of BHB810, targeting a challenging protein like CDH17, highlights the potential of AI to unlock therapeutic strategies for targets that have historically been intractable. By analyzing vast datasets and identifying subtle patterns, AI can uncover novel binding sites and optimize molecular designs in ways that might elude human researchers. This opens up new avenues for treating diseases previously considered "undruggable."
n
Personalized Medicine Advancements: The trial’s focus on patients with CDH17 expression aligns with the growing trend towards personalized medicine. By targeting specific biomarkers, therapies can be tailored to the individual patient’s tumor biology, leading to improved efficacy and reduced side effects. BigHat’s AI platform can further enhance this by identifying complex predictive biomarkers and optimizing drug design for specific patient subpopulations.
n
Validation of AI as a Core Competency: The success of BigHat Biosciences validates AI as a core competency for biotechnology and pharmaceutical companies. The significant investments made by major players like Eli Lilly in AI-driven antibody discovery underscore the industry’s recognition of its transformative potential. This trend is likely to accelerate, leading to increased competition and innovation in the AI-powered drug development space.
n
Impact on Gastric and GI Cancers: For patients suffering from advanced gastric and gastroesophageal cancers, BHB810 represents a beacon of hope. The promising preclinical data and the commencement of human trials suggest a potential for a new, effective treatment option. Given the often-poor prognosis associated with these cancers, any advancement in therapeutic efficacy and safety is profoundly significant. The success of BHB810 could pave the way for a new generation of targeted therapies for these devastating diseases.
In conclusion, the dosing of the first patient in the BHB810 Phase I clinical trial by BigHat Biosciences is a landmark event. It not only signifies a critical step in the development of a potential new therapy for GI cancers but also powerfully illustrates the transformative impact of artificial intelligence on the future of medicine. As BigHat continues to advance its pipeline and leverage its AI platform, the biotech industry watches with keen interest, anticipating further breakthroughs that promise to reshape how we discover, develop, and deliver life-saving treatments.
